Riluzole in Patients With Spinocerebellar Ataxia Type 7

Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months in the treated group.

Placebo drug for 6 months, however they will receive riluzole during the last 6 months of study, so that all patients will undergo the active drug in the last phase of the study.